Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Neuralgia Treatment Market

Neuralgia Treatment Market Share

Report ID: GMI12778
Published Date: Dec 2024
Report Format: PDF

Download Free Sample

Neuralgia Treatment Market Share

Several key players in the medical market are making strides in product innovation and strategic partnerships to maintain market leadership. Companies are investing heavily in R&D to develop advanced drainage systems with enhanced features such as advancements in pharmacological therapies, adoption of digital health solutions, and emergence of minimally invasive procedures. Additionally, partnerships with healthcare providers are being forged to improve product accessibility in emerging markets.

Regulatory compliance and adherence to international quality standards are crucial aspects of the strategies employed by these companies to cater to a global market. These developments are helping companies meet the increasing demand for safe and efficient neuralgia treatment solutions.

Neuralgia Treatment Market Companies

Prominent players operating in the neuralgia treatment industry include:

AA pharma
astellas
Biogen
Eli Lilly
Johnson & Johnson
Medtronic
NOVARTIS
PACIRA BIOSCIENCES
Pfizer
Siemens Healthineers

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global neuralgia treatment industry was valued at USD 2.4 billion in 2024 and is projected to grow at a CAGR of 7.7% from 2025 to 2034, driven by the rising prevalence of neurological disorders and improved diagnosis rates.

The surgical procedures segment is expected to grow at a CAGR of 7.5%, reaching over USD 3.3 billion by 2034, as these procedures address the root causes of pain, such as nerve compression or damage.

The U.S. neuralgia treatment market was valued at USD 1 billion in 2024 and is anticipated to grow at a CAGR of 7.1% from 2025 to 2034, supported by advanced medical technologies and innovative treatment options.

Surgical procedures, such as microvascular decompression (MVD) and nerve grafting, are preferred for severe or treatment-resistant neuralgia as they target the underlying causes of pain effectively.

Key players in the market include AA Pharma, Astellas, Biogen, Eli Lilly, Johnson & Johnson, Medtronic, Novartis, Pacira Biosciences, and Pfizer.